Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

226 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and Pharmacokinetics of Double-Dose Lopinavir/Ritonavir + Rifampin Versus Lopinavir/Ritonavir + Daily Rifabutin for Treatment of Human Immunodeficiency Virus-Tuberculosis Coinfection.
Kendall MA, Lalloo U, Fletcher CV, Wu X, Podany AT, Cardoso SW, Ive P, Benson CA. Kendall MA, et al. Among authors: benson ca. Clin Infect Dis. 2021 Aug 16;73(4):706-715. doi: 10.1093/cid/ciab097. Clin Infect Dis. 2021. PMID: 34398956 Free PMC article. Clinical Trial.
Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients.
Benson CA, Deeks SG, Brun SC, Gulick RM, Eron JJ, Kessler HA, Murphy RL, Hicks C, King M, Wheeler D, Feinberg J, Stryker R, Sax PE, Riddler S, Thompson M, Real K, Hsu A, Kempf D, Japour AJ, Sun E. Benson CA, et al. J Infect Dis. 2002 Mar 1;185(5):599-607. doi: 10.1086/339014. Epub 2002 Feb 14. J Infect Dis. 2002. PMID: 11865416 Clinical Trial.
A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of disseminated Mycobacterium avium complex disease in persons with acquired immunodeficiency syndrome.
Benson CA, Williams PL, Currier JS, Holland F, Mahon LF, MacGregor RR, Inderlied CB, Flexner C, Neidig J, Chaisson R, Notario GF, Hafner R; AIDS Clinical Trials Group 223 Protocol Team. Benson CA, et al. Clin Infect Dis. 2003 Nov 1;37(9):1234-43. doi: 10.1086/378807. Epub 2003 Oct 3. Clin Infect Dis. 2003. PMID: 14557969 Clinical Trial.
A randomized trial of treatment interruption before optimized antiretroviral therapy for persons with drug-resistant HIV: 48-week virologic results of ACTG A5086.
Benson CA, Vaida F, Havlir DV, Downey GF, Lederman MM, Gulick RM, Glesby MJ, Wantman M, Bixby CJ, Rinehart AR, Snyder S, Wang R, Patel S, Mellors JW; ACTG A5086 Study Team. Benson CA, et al. J Infect Dis. 2006 Nov 1;194(9):1309-18. doi: 10.1086/508289. Epub 2006 Sep 22. J Infect Dis. 2006. PMID: 17041858 Clinical Trial.
Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America.
Deeks SG, Gange SJ, Kitahata MM, Saag MS, Justice AC, Hogg RS, Eron JJ, Brooks JT, Rourke SB, Gill MJ, Bosch RJ, Benson CA, Collier AC, Martin JN, Klein MB, Jacobson LP, Rodriguez B, Sterling TR, Kirk GD, Napravnik S, Rachlis AR, Calzavara LM, Horberg MA, Silverberg MJ, Gebo KA, Kushel MB, Goedert JJ, McKaig RG, Moore RD. Deeks SG, et al. Among authors: benson ca. Clin Infect Dis. 2009 Nov 15;49(10):1582-90. doi: 10.1086/644768. Clin Infect Dis. 2009. PMID: 19845473 Free PMC article.
Late presentation for human immunodeficiency virus care in the United States and Canada.
Althoff KN, Gange SJ, Klein MB, Brooks JT, Hogg RS, Bosch RJ, Horberg MA, Saag MS, Kitahata MM, Justice AC, Gebo KA, Eron JJ, Rourke SB, Gill MJ, Rodriguez B, Sterling TR, Calzavara LM, Deeks SG, Martin JN, Rachlis AR, Napravnik S, Jacobson LP, Kirk GD, Collier AC, Benson CA, Silverberg MJ, Kushel M, Goedert JJ, McKaig RG, Van Rompaey SE, Zhang J, Moore RD. Althoff KN, et al. Among authors: benson ca. Clin Infect Dis. 2010 Jun 1;50(11):1512-20. doi: 10.1086/652650. Clin Infect Dis. 2010. PMID: 20415573 Free PMC article.
No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT.
Ribaudo HJ, Benson CA, Zheng Y, Koletar SL, Collier AC, Lok JJ, Smurzynski M, Bosch RJ, Bastow B, Schouten JT; ACTG A5001/ALLRT Protocol Team. Ribaudo HJ, et al. Among authors: benson ca. Clin Infect Dis. 2011 Apr 1;52(7):929-40. doi: 10.1093/cid/ciq244. Clin Infect Dis. 2011. PMID: 21427402 Free PMC article. Clinical Trial.
Incidence of non-AIDS-defining cancer in antiretroviral treatment-naïve subjects after antiretroviral treatment initiation: an ACTG longitudinal linked randomized trials analysis.
Krishnan S, Schouten JT, Jacobson DL, Benson CA, Collier AC, Koletar SL, Santana J, Sattler FR, Mitsuyasu R; ACTG-ALLRT Protocol Team. Krishnan S, et al. Among authors: benson ca. Oncology. 2011;80(1-2):42-9. doi: 10.1159/000328032. Epub 2011 May 23. Oncology. 2011. PMID: 21606663 Free PMC article.
Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study.
Luetkemeyer AF, Rosenkranz SL, Lu D, Marzan F, Ive P, Hogg E, Swindells S, Benson CA, Grinsztejn B, Sanne IM, Havlir DV, Aweeka F; Adult AIDS Clinical Trials Group A5221 Study Team. Luetkemeyer AF, et al. Among authors: benson ca. Clin Infect Dis. 2013 Aug;57(4):586-93. doi: 10.1093/cid/cit246. Epub 2013 Apr 16. Clin Infect Dis. 2013. PMID: 23592830 Free PMC article.
226 results